drugset / Trial / NCT00584402

Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

NCT00584402

Completed 8 enrolled University of California, Davis
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas \& metastases) within the liver. Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

Timeline

Start
2007-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Definity Diagnostic / imaging agent 0.1 ml Intravenous